(Albany, USA) DelveInsight’s “Pruritus Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Pruritus, historical and forecasted epidemiology as well as the Pruritus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Pruritus market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Pruritus market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Pruritus treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Pruritus market.
Request for a Free Sample Report @ Pruritus Market Forecast
Some facts of the Pruritus Market Report are:
- According to DelveInsight, Pruritus market size is expected to grow at a decent CAGR by 2032.
- Leading Pruritus companies working in the market are GlaxoSmithKline, Asana BioSciences, Vanda Pharmaceuticals, Trevi Therapeutics, Lumosa Therapeutics, Shandong Boan Biotechnology, Sichuan Haisco Pharmaceutical, Escient Pharmaceuticals, MC2 Therapeutics, Avior Bio, AOBiome Therapeutics, Clexio Biosciences, BioMimetix, Titan Pharmaceuticals, Teikoku Pharma, Tioga Pharmaceuticals, Chugai Pharmaceutical, Suzhou Connect Biopharmaceuticals, Klus Pharma, Akaal Pharma, Nocion Therapeutics, Saniona, Akari Therapeutics, Regeneron Pharmaceuticals; Sanofi-Aventis, and others.
- In February 2025, Sanofi announced findings of Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO).
- In February 2025, Mirum Pharmaceuticals, Inc announced results of a Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants with Cholestatic Pruritus
- In December 2024, Tharimmune Inc announced evaluation of TH104 for Moderate to Severe Pruritus in Primary Biliary Cholangitis: a Double-blind, Randomized, Placebo-controlled, Phase 2a Study
- In July 2024, Nexgen Dermatologics, Inc.tested Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in the Treatment of Patients With Mild Atopic Dermatitis
- Rising prevalence of target diseases, unmet needs of pruritus patients pushing the drug development, significant focus of pharmaceutical companies on development of novel mechanisms based pruritus drugs, upcoming patent expiry, availability of public as well private funds for research, and favorable regulatory scenario, are some of the key factors propelling market growth in the industry.
Pruritus Overview
Pruritus or itchy skin is an unusual, unforgettable, and unwanted sensitivity that leads to an urge to scratch. Pruritis is often caused due to lack of moisture in the skin. It is commonly seen in old age and deteriorates over time. The pruritus rash or itchiness may appear normal, red, or rough to the touch. The person’s skin may appear thick and blood-red when scratched vigorously, leading to infection.
Pruritus can affect areas such as the scalp, legs, arms, and small body areas. Itchy skin can be further associated with redness, irritation, dampness, dry and cracked skin, and sometimes blisters and patches in severe cases. Irritation can last upto more than six weeks and severely affect the quality of your life.
Learn more about Pruritus treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/pruritis-market
Pruritus Market
The Pruritus market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Pruritus market trends by analyzing the impact of current Pruritus therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Pruritus market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Pruritus market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The pruritus market is driven by the rising prevalence of chronic skin conditions, advancements in targeted therapies, and increasing awareness of the condition’s impact on quality of life. Factors such as atopic dermatitis, psoriasis, kidney disease, and liver disorders contribute to the growing patient population experiencing pruritus. The development of novel therapies, including NK-1 receptor antagonists, IL-31 inhibitors, and JAK inhibitors, has expanded treatment options beyond traditional antihistamines and corticosteroids.
Additionally, improved diagnostic tools and patient-centered research are enhancing disease management. However, the market faces barriers, including the high cost of advanced biologics, limited treatment efficacy for certain underlying causes, and challenges in identifying the exact pathophysiology of chronic pruritus. Many cases remain undertreated due to misdiagnosis or lack of awareness, and side effects associated with systemic treatments can impact patient adherence. Despite these challenges, ongoing clinical trials, increased investment in dermatological R&D, and growing recognition of pruritus as a debilitating condition are expected to drive future market growth.
According to DelveInsight, the Pruritus market in 7MM is expected to witness a major change in the study period 2019-2032.
Pruritus Epidemiology
The Pruritus epidemiology section provides insights into the historical and current Pruritus patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Pruritus market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Pruritus Epidemiology at: @ Pruritus Prevalence
Pruritus Drugs Uptake
This section focuses on the uptake rate of the potential Pruritus drugs recently launched in the Pruritus market or expected to be launched in 2019-2032. The analysis covers the Pruritus market uptake by drugs, patient uptake by therapies, and sales of each drug.
Pruritus Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Pruritus market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Pruritus Pipeline Development Activities
The Pruritus report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses key Pruritus companies involved in developing targeted therapeutics.
Request for a sample report to understand more about the Pruritus pipeline development activities @ Pruritus Companies and Therapies
Pruritus Therapeutics Assessment
Several prominent companies are actively involved in the Pruritus Therapeutics market, striving to develop innovative therapies that will drive advancements in Pruritus treatment. These companies include GlaxoSmithKline, Asana BioSciences, Vanda Pharmaceuticals, Trevi Therapeutics, Lumosa Therapeutics, Shandong Boan Biotechnology, Sichuan Haisco Pharmaceutical, Escient Pharmaceuticals, MC2 Therapeutics, Avior Bio, AOBiome Therapeutics, Clexio Biosciences, BioMimetix, Titan Pharmaceuticals, Teikoku Pharma, Tioga Pharmaceuticals, Chugai Pharmaceutical, Suzhou Connect Biopharmaceuticals, Klus Pharma, Akaal Pharma, Nocion Therapeutics, Saniona, Akari Therapeutics, Regeneron Pharmaceuticals, Sanofi-Aventis, and others. These companies are actively engaged in research and development efforts to bring forth novel therapeutic options and contribute to the progress of the Pruritus Therapeutics market in the coming years.
Learn more about the emerging Pruritus therapies & key companies @ Pruritus Clinical Trials and Advancements
Pruritus Report Key Insights
1. Pruritus Patient Population
2. Pruritus Market Size and Trends
3. Key Cross Competition in the Pruritus Market
4. Pruritus Market Dynamics (Key Drivers and Barriers)
5. Pruritus Market Opportunities
6. Pruritus Therapeutic Approaches
7. Pruritus Pipeline Analysis
8. Pruritus Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Pruritus Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Pruritus Competitive Intelligence Analysis
4. Pruritus Market Overview at a Glance
5. Pruritus Disease Background and Overview
6. Pruritus Patient Journey
7. Pruritus Epidemiology and Patient Population
8. Pruritus Treatment Algorithm, Current Treatment, and Medical Practices
9. Pruritus Unmet Needs
10. Key Endpoints of Pruritus Treatment
11. Pruritus Marketed Products
12. Pruritus Emerging Therapies
13. Pruritus Seven Major Market Analysis
14. Attribute Analysis
15. Pruritus Market Outlook (7 major markets)
16. Pruritus Access and Reimbursement Overview
17. KOL Views on the Pruritus Market
18. Pruritus Market Drivers
19. Pruritus Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting